Therapy Areas: Devices
Immuron signs US distribution deal for PROIBS
4 September 2026 - Australian biopharmaceutical company Immuron Limited (ASX: IMC; NASDAQ: IMRN), which develops and commercialises targeted polyclonal antibodies for infectious diseases, announced on...
Tempus announces receipt of FDA clearance for AI pulmonary hypertension detection product
24 August 2026 - Medical technology company Tempus AI Inc (NASDAQ: TEM) reported on Monday that it has received 510(k) clearance from the U.S. Food and Drug Administration for Tempus ECG-PH, an AI-ena...
Pulnovo Medical commences enrolment in PULSE-LHD IDE clinical trial
24 August 2026 - Medical technology company Pulnovo Medical announced on Sunday the enrolment of the first two patients in its PULSE-LHD clinical trial, conducted under a US Food and Drug Administrati...
Implantica's RefluxStop receives US FDA approval
21 August 2026 - Medical technology company Implantica AG (Nasdaq First North Premier Growth Market: IMP A SDB) announced on Thursday that the US Food and Drug Administration (FDA) has granted Premark...
Sectra to provide Education Portal to Loyalist College for medical imaging training
19 August 2026 - Sectra (STO: SECT B), a medical imaging IT and cybersecurity company, announced on Wednesday that it will provide its cloud-based Education Portal to Loyalist College in Ontario, Cana...
Aqua Medical treats second type 2 diabetes patient in IDE trial of investigational PIMA procedure
19 August 2026 - Aqua Medical Inc, a clinical-stage medical technology company advancing Endoscopic Metabolic Restoration, announced on Tuesday the treatment of the first West Coast patient (second ov...